Alcon Reports Strong Q1 Sales Growth Despite EPS Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2025
0mins
Should l Buy ALC?
Source: Investing
Alcon AG's stock fell 11.83% and hit a 52-week low amid broader market gains, with the Nasdaq-100 up 1.05% and the S&P 500 up 0.74%.
The company's Q1 2026 sales reached $2.7 billion, marking a 10% increase year-over-year, although diluted EPS declined 44% to $0.39. Despite this, core diluted EPS rose 16% to $0.85, reflecting improved profitability driven by innovative product launches. Additionally, Alcon approved a CHF 0.28 dividend and announced a $1.5 billion share repurchase program, indicating strong shareholder confidence and commitment to enhancing shareholder value.
The mixed earnings report highlights Alcon's robust sales growth but raises concerns about profitability due to the significant drop in diluted EPS. The company's ongoing initiatives, including the share repurchase program, may help stabilize investor sentiment moving forward.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALC
Wall Street analysts forecast ALC stock price to rise
13 Analyst Rating
7 Buy
5 Hold
1 Sell
Moderate Buy
Current: 63.880
Low
78.17
Averages
93.73
High
117.26
Current: 63.880
Low
78.17
Averages
93.73
High
117.26
About ALC
Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alcon Q1 2026 Earnings Call Insights Highlight Strong Market Gains
- Significant Sales Growth: Alcon reported Q1 sales of $2.7 billion, a 6% increase year-over-year, with surgical equipment sales reaching $253 million, up 23%, indicating strong momentum from the Unity product line that is expected to further enhance market share.
- Strong New Product Performance: The PanOptix Pro has driven nearly 2 percentage points of growth in the U.S. PC-IOL category, while Tryptyr has captured approximately 4 percentage points of market share just 8 months post-launch, demonstrating the company's ongoing competitiveness in the dry eye segment.
- Share Repurchase Program: The Board has approved a new $1.5 billion share repurchase program to be executed over the next three years, which is expected to be supported by an estimated $25 million reduction in tariff expenses earmarked for reinvestment, thereby enhancing shareholder value.
- Optimistic Future Outlook: The company continues to expect sales growth of 5% to 7% for 2026, with an aggregate eye care market growth assumption of 3% to 4%, while core diluted EPS is projected to grow between 10% and 13%, reflecting management's confidence in the market.
See More
Alcon (ALC) Q1 2026 Earnings Call Transcript
See More
Alcon Reports Mixed Q1 Results, Stock Drops Over 10%
- Mixed Performance: Alcon's Q1 revenue of $2.7 billion fell short of analysts' expectations by $10 million, resulting in a 10.58% drop in stock price to $66.25, reflecting market disappointment with the company's performance.
- Sales Driven by New Products: Despite the revenue miss, Alcon's new products like Unity VCS and PanOptix Pro helped surgical net sales reach $1.5 billion, a 10% year-on-year increase, indicating strong market potential for these innovations.
- Decline in Operating Income: The company's operating income fell 38% to $292 million, with operating margin decreasing by 8.2 percentage points, primarily due to costs associated with efficiency initiatives and increased R&D expenses, highlighting challenges in cost management.
- Optimistic Future Outlook: Alcon raised its core EPS growth outlook for 2026 to 10%-13% and expects net sales growth between 5%-7%, demonstrating confidence in future market conditions despite current short-term challenges.
See More
Alcon Reports 10% Sales Growth in Q1 2026
- Strong Sales Performance: Alcon's Q1 2026 sales reached $2.7 billion, marking a 10% increase year-over-year, with a 6% rise on a constant currency basis, indicating robust demand and performance in the eye care market.
- Earnings Per Share Fluctuation: The diluted EPS for Q1 was $0.39, down 44% year-over-year, while core diluted EPS rose 16% to $0.85, reflecting improved profitability driven by innovative product launches.
- Shareholder Return Initiatives: The company approved a dividend of CHF 0.28 per share at the AGM and announced a $1.5 billion share repurchase program over three years, aimed at enhancing shareholder value and optimizing capital structure.
- Market Outlook Update: Alcon maintains its 2026 sales growth forecast at 5% to 7% and raises its core diluted EPS growth outlook to 10% to 13%, demonstrating confidence in future market conditions and ongoing innovation capabilities.
See More
PerZeption Collaborates with Alcon to Advance Vision Assessment Technology
- Technology Validation Showcase: PerZeption will present new data on its AIM+ CSF modeling technology at the 2026 ARVO annual meeting, demonstrating the technology's ability to rapidly, repeatably, and sensitively assess contrast vision, thereby enhancing the precision and efficiency of vision correction evaluations.
- Clinical Research Findings: The study indicates that with six adaptive stimulus displays and two repeats, approximately 20 subjects can achieve 90% power to detect a 1 JND (Just Noticeable Difference) change, validating AIM+ CSF's effectiveness in visual performance evaluation.
- Partnership Commitment: The collaboration with Alcon, one of the largest companies in the ophthalmology sector, underscores a shared dedication to advancing ophthalmology research and developing precise visual assessment tools, which is expected to drive technological advancements in the industry.
- Demonstration Opportunities: During the ARVO meeting, PerZeption will also showcase its battery of functional tests at booth #4027, providing attendees with the opportunity to experience the technology firsthand, further enhancing its influence in the field of visual assessment.
See More
Alcon Shareholders Approve All Agenda Items at AGM
- AGM Approval: At the 2026 Annual General Meeting, Alcon shareholders approved all proposed resolutions, with a total of 283,222,421 shares represented, amounting to an aggregate nominal value of CHF 11,328,896.84, reflecting strong shareholder confidence in the company's future.
- Board Elections: Shareholders re-elected F. Michael Ball as Chair and elected R. Scott Herren as a new independent board member, enhancing board diversity and independence, which is crucial for improving corporate governance.
- Compensation Reports: The shareholders approved the 2025 Compensation Report and the Report on Non-Financial Matters in consultative votes, demonstrating the company's commitment to transparency and accountability, which can strengthen investor trust.
- Dividend Declaration: A gross dividend of CHF 0.28 per share was approved, indicating the company's financial stability and commitment to returning value to shareholders, thereby enhancing shareholder value.
See More
Alcon Q1 2026 Earnings Call Insights Highlight Strong Market Gains
- Significant Sales Growth: Alcon reported Q1 sales of $2.7 billion, a 6% increase year-over-year, with surgical equipment sales reaching $253 million, up 23%, indicating strong momentum from the Unity product line that is expected to further enhance market share.
- Strong New Product Performance: The PanOptix Pro has driven nearly 2 percentage points of growth in the U.S. PC-IOL category, while Tryptyr has captured approximately 4 percentage points of market share just 8 months post-launch, demonstrating the company's ongoing competitiveness in the dry eye segment.
- Share Repurchase Program: The Board has approved a new $1.5 billion share repurchase program to be executed over the next three years, which is expected to be supported by an estimated $25 million reduction in tariff expenses earmarked for reinvestment, thereby enhancing shareholder value.
- Optimistic Future Outlook: The company continues to expect sales growth of 5% to 7% for 2026, with an aggregate eye care market growth assumption of 3% to 4%, while core diluted EPS is projected to grow between 10% and 13%, reflecting management's confidence in the market.
See More
Alcon (ALC) Q1 2026 Earnings Call Transcript
See More
Alcon Reports Mixed Q1 Results, Stock Drops Over 10%
- Mixed Performance: Alcon's Q1 revenue of $2.7 billion fell short of analysts' expectations by $10 million, resulting in a 10.58% drop in stock price to $66.25, reflecting market disappointment with the company's performance.
- Sales Driven by New Products: Despite the revenue miss, Alcon's new products like Unity VCS and PanOptix Pro helped surgical net sales reach $1.5 billion, a 10% year-on-year increase, indicating strong market potential for these innovations.
- Decline in Operating Income: The company's operating income fell 38% to $292 million, with operating margin decreasing by 8.2 percentage points, primarily due to costs associated with efficiency initiatives and increased R&D expenses, highlighting challenges in cost management.
- Optimistic Future Outlook: Alcon raised its core EPS growth outlook for 2026 to 10%-13% and expects net sales growth between 5%-7%, demonstrating confidence in future market conditions despite current short-term challenges.
See More
Alcon Reports 10% Sales Growth in Q1 2026
- Strong Sales Performance: Alcon's Q1 2026 sales reached $2.7 billion, marking a 10% increase year-over-year, with a 6% rise on a constant currency basis, indicating robust demand and performance in the eye care market.
- Earnings Per Share Fluctuation: The diluted EPS for Q1 was $0.39, down 44% year-over-year, while core diluted EPS rose 16% to $0.85, reflecting improved profitability driven by innovative product launches.
- Shareholder Return Initiatives: The company approved a dividend of CHF 0.28 per share at the AGM and announced a $1.5 billion share repurchase program over three years, aimed at enhancing shareholder value and optimizing capital structure.
- Market Outlook Update: Alcon maintains its 2026 sales growth forecast at 5% to 7% and raises its core diluted EPS growth outlook to 10% to 13%, demonstrating confidence in future market conditions and ongoing innovation capabilities.
See More
PerZeption Collaborates with Alcon to Advance Vision Assessment Technology
- Technology Validation Showcase: PerZeption will present new data on its AIM+ CSF modeling technology at the 2026 ARVO annual meeting, demonstrating the technology's ability to rapidly, repeatably, and sensitively assess contrast vision, thereby enhancing the precision and efficiency of vision correction evaluations.
- Clinical Research Findings: The study indicates that with six adaptive stimulus displays and two repeats, approximately 20 subjects can achieve 90% power to detect a 1 JND (Just Noticeable Difference) change, validating AIM+ CSF's effectiveness in visual performance evaluation.
- Partnership Commitment: The collaboration with Alcon, one of the largest companies in the ophthalmology sector, underscores a shared dedication to advancing ophthalmology research and developing precise visual assessment tools, which is expected to drive technological advancements in the industry.
- Demonstration Opportunities: During the ARVO meeting, PerZeption will also showcase its battery of functional tests at booth #4027, providing attendees with the opportunity to experience the technology firsthand, further enhancing its influence in the field of visual assessment.
See More
Alcon Shareholders Approve All Agenda Items at AGM
- AGM Approval: At the 2026 Annual General Meeting, Alcon shareholders approved all proposed resolutions, with a total of 283,222,421 shares represented, amounting to an aggregate nominal value of CHF 11,328,896.84, reflecting strong shareholder confidence in the company's future.
- Board Elections: Shareholders re-elected F. Michael Ball as Chair and elected R. Scott Herren as a new independent board member, enhancing board diversity and independence, which is crucial for improving corporate governance.
- Compensation Reports: The shareholders approved the 2025 Compensation Report and the Report on Non-Financial Matters in consultative votes, demonstrating the company's commitment to transparency and accountability, which can strengthen investor trust.
- Dividend Declaration: A gross dividend of CHF 0.28 per share was approved, indicating the company's financial stability and commitment to returning value to shareholders, thereby enhancing shareholder value.
See More
